Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 1/20 | 0.32 |
| ▸ | BRD2 | P25440 | 1/20 | 0.32 |
| ▸ | BRD3 | Q15059 | 1/20 | 0.32 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.32 |
| ▸ | HSP90B1 | P14625 | 1/20 | 0.32 |
| ▸ | DHFR | P00374 | 1/20 | 0.32 |
| ▸ | TYMS | P04818 | 1/20 | 0.32 |
| ▸ | PTGDR2 | Q9Y5Y4 | 2/20 | 0.31 |
| ▸ | CRHR1 | P34998 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5750378 | 0.94 | PTGDR2 (0.34) | BRD4BRD2BRD3CREBBPHSP90B1 | |
| SCHEMBL5753821 | 0.90 | HSP90B1 (0.32) | BRD4BRD2BRD3CREBBPHSP90B1 | |
| SCHEMBL5751729 | 0.82 | HSP90B1 (0.32) | HSP90B1 | |
| SCHEMBL5752055 | 0.81 | SLC22A12 (0.35) | BRD4BRD2BRD3CREBBPDHFR | |
| SCHEMBL5754079 | 0.78 | L3MBTL1 (0.36) | BRD4BRD2BRD3CREBBP | |
| SCHEMBL5752981 | 0.77 | MARS1 (0.34) | BRD4BRD2BRD3CREBBPHSP90B1 | |
| SCHEMBL5750482 | 0.76 | TYMS (0.34) | HSP90B1DHFRTYMS | |
| SCHEMBL5752390 | 0.75 | PGR (0.33) | HSP90B1 | |
| SCHEMBL5802472 | 0.73 | — | — | |
| SCHEMBL5751439 | 0.73 | L3MBTL1 (0.41) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7141585-B2 | Pyrazole derivatives | AGOURON PHARMACEUTICALS, INC. (US) | 2006-11-28 | — | — | US | claimed |
| EP-1299361-B1 | PYRAZOLE DERIVATIVES | PFIZER LTD (GB) | 2006-07-19 | — | — | EP | claimed |
| US-20040209862-A1 | Pyrazole derivatives | PFIZER, INC. | 2004-10-21 | — | — | US | claimed |
| US-6750230-B2 | use treating Human Immunodeficiency Virus (HIV) , or genetically related retroviral, infection or a resulting acquired immunodeficiency syndrome (AIDS); 2-[4-(3,5-dichlorobenzyl)-3,5-diethyl-1H-pyrazol-1-yl]ethanol for example; reverse transcriptase inhibitors | PFIZER, INC. | 2004-06-15 | — | — | US | claimed |
| EP-1299361-A1 | PYRAZOLE DERIVATIVES | Pfizer Limited (GB) | 2003-04-09 | — | — | EP | claimed |
| WO-2002004424-A9 | PYRAZOLE DERIVATIVES | PFIZER LTD (GB) | 2002-12-12 | — | — | WO | claimed |
| US-20020032184-A1 | Pyrazole derivatives | PFIZER INC. | 2002-03-14 | — | — | US | claimed |
| WO-2002004424-A1 | PYRAZOLE DERIVATIVES | PFIZER LIMITED (GB) | 2002-01-17 | — | — | WO | claimed |
| US-7141585-B2 | Pyrazole derivatives | AGOURON PHARMACEUTICALS, INC. (US) | 2006-11-28 | — | — | US | disclosed |
| EP-1299361-B1 | PYRAZOLE DERIVATIVES | PFIZER LTD (GB) | 2006-07-19 | — | — | EP | disclosed |
| US-20040209862-A1 | Pyrazole derivatives | PFIZER, INC. | 2004-10-21 | — | — | US | disclosed |
| US-6750230-B2 | use treating Human Immunodeficiency Virus (HIV) , or genetically related retroviral, infection or a resulting acquired immunodeficiency syndrome (AIDS); 2-[4-(3,5-dichlorobenzyl)-3,5-diethyl-1H-pyrazol-1-yl]ethanol for example; reverse transcriptase inhibitors | PFIZER, INC. | 2004-06-15 | — | — | US | disclosed |
| EP-1299361-A1 | PYRAZOLE DERIVATIVES | Pfizer Limited (GB) | 2003-04-09 | — | — | EP | disclosed |
| WO-2002004424-A9 | PYRAZOLE DERIVATIVES | PFIZER LTD (GB) | 2002-12-12 | — | — | WO | disclosed |
| US-20020032184-A1 | Pyrazole derivatives | PFIZER INC. | 2002-03-14 | — | — | US | disclosed |
| WO-2002004424-A1 | PYRAZOLE DERIVATIVES | PFIZER LIMITED (GB) | 2002-01-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020032184-A1 | Pyrazole derivatives | POLRMT, TPMT, CYP3A43 | BRD4 452/4885BRD2 1350/4885BRD3 577/4885 |
| US-20040209862-A1 | Pyrazole derivatives | POLRMT, TPMT, CYP3A43 | BRD4 452/4885BRD2 1350/4885BRD3 577/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.